Тритаце

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Тритаце

Quick Facts

Property Description
Active ingredient Ramipril
Form Tablets (Oral preparation)
Pharmacological class ACE inhibitor
General purpose Management of blood pressure
Origin Synthetic compound (Pro-drug)

What is Тритаце?

Тритаце: What is This Type of Cardiovascular Medicine?

Тритаце is a specific brand name for a prescription-only medicine containing the active substance Ramipril. As an antihypertensive agent, its function is clinically recognized for contributing to long-term cardiovascular medication strategies. Тритаце is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. This classification confirms that the medicine is designed to systematically lower the resistance within the arteries. The general purpose is to support the controlled management of blood pressure, a central goal in maintaining heart health. ACE inhibitors are standard treatments for conditions affected by high blood pressure, confirming their established clinical use.

Ramipril: The Active Ingredient and Form

The medicinal identity of Тритаце centers on the single-ingredient active substance, Ramipril (INN). The compound is a synthetic compound supplied as an oral preparation in the form of tablets. Ramipril functions as a pro-drug. This means the ingested compound is biologically inert until the body processes it into the potent metabolite, Ramiprilat, after absorption. This necessary conversion, which distinguishes Ramipril from immediately active compounds, ensures the reliable and sustained therapeutic effect of inhibition of ACE, supporting the overall management of vascular tone.

Regulatory References

  1. ACE Inhibitors (NCBI Bookshelf)

What side effects are possible with Тритаце?

Possible Side Effects and Safety Information

The official safety profile for Tritace (Ramipril) details potential adverse reactions based on their frequency and impact on various physiological systems. The adverse events are categorized according to regulatory standards to communicate risks in a clear, structured manner, focusing exclusively on label-documented safety characteristics.


Frequency and System-Organ Classes

The most Common adverse reactions (affecting 1 to 10 users in 100) are typically observed in the Nervous system (Headache, Dizziness) and the Respiratory system (non-productive persistent Cough), a known class effect of ACE inhibitors. Other common events include symptomatic Hypotension (low blood pressure) and fatigue, classified under Vascular disorders.

Adverse events listed as Uncommon or Rare include mood alterations, skin rash, or disturbances in liver function. Certain severe effects, such as Angioedema (serious swelling of the face or throat), are listed as Not Known in frequency but constitute critical safety risks documented in official labeling.


Serious Adverse Reactions and Safety Constraints

The label highlights the risk of severe, potentially life-threatening reactions. These include Angioedema and severe Hypotension, which may result in syncope, particularly when initiating treatment or increasing the dose. The official safety constraints strictly prohibit the use of Ramipril in individuals with a history of Angioedema related to previous ACE inhibitor use and in patients with bilateral renal artery stenosis.

Safety notes also specify that Hypotension is explicitly more likely to occur at the start of treatment. Furthermore, official regulatory documents advise caution and monitoring for specific groups, such as Older Adults and patients with Renal Impairment, due to a heightened potential for accumulation or susceptibility to effects on blood pressure. The medication is formally Contraindicated during the second and third trimesters of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Tritace (Ramipril) overdose is characterized by an exaggerated primary effect on the vascular system. The most commonly documented clinical presentation is severe hypotension, or profound low blood pressure. This effect may manifest as physical signs such as lightheadedness and fainting (syncope). Severe or life-threatening manifestations are officially noted to include cardiovascular collapse and the potential for acute renal failure or hyperkalemia (elevated potassium levels).

Mandatory Emergency Action

The primary action in any suspected overdose is to seek immediate emergency medical attention. According to government health guidance, urgent help must be sought if the individual has collapsed, experiences trouble breathing, or cannot be awakened. Contacting emergency services or a Poison Help line is mandated under these conditions.

Overdose Management Profile

Regulatory documents confirm that no specific antagonist or antidote is widely available to reverse the effects of a Ramipril overdose. Management is symptomatic and supportive. The primary treatment described in prescribing information to counteract severe hypotension is the infusion of normal saline solution. The effectiveness of removing the drug from the body via hemodialysis is not established.

Therapeutic Uses of Тритаце

What Tritace Treats: Main Uses and Benefits

Tritace (Ramipril) provides therapeutic support across several critical cardiovascular and renal domains, addressing conditions marked by increased physiological stress and high-risk symptomatic patterns. The core therapeutic uses of this medication are generally considered relevant in conditions involving systemic imbalance; for instance, it may play a role in reducing the potential for cardiovascular events and supports the long-term well-being and management in certain heart patients.

It is commonly used to help manage elevated blood pressure, support patients with symptomatic chronic heart failure, and for supportive prevention in high-risk groups, including those with established vascular disease or diabetes.

“The primary goal of this therapy is to support the functional stability of the cardiovascular and renal systems.”

This medication assists in easing associated fluid accumulation and congestion symptoms, which contributes to improved day-to-day comfort during symptomatic periods. It may also contribute to supporting renal function, which assists with maintaining the stability required for routine functioning.


Quick Fact: Relief for Systemic Imbalance

Therapeutic Area Primary Symptom Axis Addressed Practical Patient Benefit
Hypertension Symptoms related to heightened physiological activity (systemic resistance) Contributes to easing the overall symptom load
Heart Failure Symptoms related to systemic imbalance (fluid accumulation and congestion) Helps improve day-to-day comfort
Prevention Symptoms linked to organ-specific functional stress (long-term risk) Assists with maintaining functional stability

Regulatory References

  1. NIH MedlinePlus overview of Ramipril

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tritace — Official Regulatory Information

Eligibility Scope Status Defined by Regulators
Populations for whom use is allowed Adults (aged 18 years) for approved indications, including cardiovascular risk reduction in patients 55.
Populations for whom use is not recommended Children and Adolescents (under 18 years), Nursing Mothers, and Pregnant Patients in the first trimester.
Populations for whom use is contraindicated History of angioedema (swelling of face/throat) related to ACE inhibitors; pregnancy in the second and third trimesters; hypersensitivity to the drug or any ACE inhibitor; hemodynamically unstable states.

Age-Related Eligibility Rules The medicine is not recommended for the pediatric population, as its safety and effectiveness have not been established. For older adults, Ramipril is permitted, but official labeling advises that a lower starting dose may be necessary.

Condition-Specific Eligibility Rules Use is highly restricted in patients with severe renal impairment and requires a mandated lower starting dose. Similarly, patients with hepatic impairment require initiation under close medical supervision and have a maximum daily dose limit. Ramipril is contraindicated in combination with Aliskiren in patients with diabetes or moderate-to-severe renal impairment, and in combination with neprilysin inhibitors (e.g., sacubitril/valsartan) due to timing restrictions.

Connection to the overall eligibility profile Official regulatory documents define a clear line between the adult population allowed to use Ramipril for approved indications and high-risk groups who are absolutely excluded (contraindicated) due to specific health conditions or concurrent therapies. Use in certain populations (e.g., those with organ impairment) is permitted only under specified conditional restrictions outlined in the prescribing information.

What should I know about interactions with other medicines?

The interaction profile for Tritace (Ramipril) is structured around official regulatory warnings regarding pharmacodynamic reinforcement and contraindicated combinations.

Contraindicated Combinations

Co-administration with Sacubitril/Valsartan is contraindicated due to the significantly increased, documented risk of angioedema. A mandatory 36-hour separation window is required when switching between these therapies. Additionally, co-administration with Aliskiren or Angiotensin II Receptor Blockers (ARBs) is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min) because of the heightened risk of hyperkalemia, hypotension, and impaired renal function. Extracorporeal treatments using certain high-flux membranes are also contraindicated due to the risk of severe anaphylactoid reactions.

Pharmacodynamic and Exposure Interactions

The co-administration of Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride) or Potassium Supplements is associated with a risk of hyperkalemia (elevated serum potassium levels). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can attenuate the antihypertensive effect and increase the risk of renal function deterioration. Co-administration with Lithium is documented to increase serum lithium concentrations, raising the risk of toxicity. Exposure of the parent drug, Ramipril, is increased in patients with hepatic impairment.

Mechanism of Action

Тритаце, whose active substance is ramipril, functions as a prodrug which undergoes hydrolysis primarily in the liver by carboxylesterase 1 to form its active metabolite, ramiprilat. Ramiprilat acts as a competitive inhibitor of the metallopeptidase angiotensin-converting enzyme (ACE), which is also known as kininase II. The primary biological target is the zinc-containing active site of ACE, which is found in both the circulation and tissues, particularly the vascular endothelium.

Inhibition of ACE prevents the conversion of the decapeptide angiotensin I to the potent vasoconstrictor angiotensin II (Ang II). This intervention into the Renin-Angiotensin-Aldosterone System (RAAS) leads to a concentration-dependent decrease in plasma and tissue levels of Ang II. The resulting reduction in Ang II prevents its binding and subsequent activation of the G-protein coupled Angiotensin II Type 1 receptor (AT1R). The downstream consequence of reduced AT1R signaling is decreased G q coupling and subsequent suppression of intracellular pathways, including the inositol triphosphate ( IP3) pathway and activation of phospholipases.

Furthermore, ACE inhibition impedes the enzymatic degradation of the vasodilator bradykinin, increasing its concentration and enhancing its B2 receptor-mediated effects, including nitric oxide synthesis. The combined molecular effect is a reduction in peripheral vascular resistance due to arterial vasodilation, and a decrease in aldosterone secretion, which modulates sodium and water reabsorption in the renal tubules. The system-level physiological consequence is a decrease in overall blood pressure.

Dosage and Administration Information

How Тритаце (Ramipril) is Used: Official Administration Guidelines

Ramipril (Тритаце) is a medication intended for oral administration and is supplied as a tablet or capsule, which must be swallowed whole with liquid; it should not be chewed or crushed. The medicine can be taken with or without food, as the relationship to meals does not significantly affect its absorption.


The administration protocol is defined by a process of gradual titration. Therapy typically begins with a low dose, often 1.25 mg or 2.5 mg, taken once daily. For specific conditions, such as post-myocardial infarction heart failure, a twice-daily schedule is used. Dose adjustments are performed over intervals, such as every two to four weeks, until a targeted maintenance dose is reached. The official maximum daily dose is 10 mg in many regions, but may be up to 20 mg in others.


Special procedural constraints apply to specific populations. Patients with renal or hepatic impairment, as well as older adults, often require a lower initial dose and a restricted maximum daily dosage, sometimes as low as 1.25 mg or a 5 mg daily maximum. It is also a procedural consideration to interrupt or reduce concurrent diuretic therapy for a few days before starting Ramipril, or to ensure the lowest starting dose is used. If a dose is missed, the general practice is to skip the missed dose and resume the schedule at the next designated time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tritace (Ramipril)

This overview summarizes the clinical research and scientific studies that was evaluated in Ramipril (Tritace), focusing on the types of trials conducted, the populations included, and the kinds of outcomes observed. This information was observed in authoritative regulatory reviews and high-quality peer-reviewed literature.


Evidence from Large-Scale Trials for Major Cardiovascular Outcomes

The evidence base for Ramipril in high-risk patients was evaluated in major, long-term, international Randomized Controlled Trials (RCTs). These studies was studied for how the medicine was associated with large-scale health events over several years.

Research examined adult populations, typically those aged 55 or older, who already had established vascular disease or Diabetes along with other risk factors, but without clinical signs of heart failure. The findings apply only to the populations studied; evidence for individuals who already had overt heart failure at the start of these trials remains limited in this specific research set.


Research Evidence Related to High Blood Pressure (Hypertension)

Ramipril was studied for its role in high blood pressure through numerous RCTs, comparative trials, and large Meta-analyses. The studies primarily evaluated adults diagnosed with essential hypertension. Comparative studies examined differences in measured BP levels between the Ramipril group, a placebo, or other classes of blood pressure medications. While the measured BP patterns appear to be consistent with the therapeutic class, comparative evidence is lacking for direct, long-term comparison against all other similar compounds when examining non-fatal heart outcomes.


Studies on Heart and Kidney Support in Specific Patient Groups

Separate placebo-controlled RCTs was evaluated in patients who had recently experienced an Acute Myocardial Infarction (MI) and subsequently developed clinical signs of Heart Failure. Studies monitored outcomes related to Overall Mortality and hospitalization due to the exacerbation of Heart Failure symptoms.

Research also explored the evaluation of Ramipril in relation to kidney function outcomes in patients with Diabetes Mellitus. Studies explored outcomes related to functional limitations by measuring markers like the amount of protein in the urine. Data directly addressing the prevention of end-stage kidney disease (ESRD) in these specific trials is limited.


Areas of Research Uncertainty and Study Gaps

While extensive research exists, certain areas remain where evidence is limited or requires more study. Specific information for individuals who already have severe, pre-existing kidney impairment at the start of treatment remains insufficient in the official trial records, as these individuals were often excluded from the definitive cardiovascular studies. This highlights what is known—and what is still uncertain—within the broader evidence landscape.

Key Studies & References

  1. Hypertension in adults: diagnosis and management (NICE Guideline NG136)

Frequently Asked Questions (FAQ)

Common questions about Тритаце (FAQ)


Q: Is Tritace a blood thinner or a beta blocker?

Official regulatory documents classify Tritace, whose active ingredient is Ramipril, as an Angiotensin-Converting Enzyme (ACE) inhibitor. This means it works by blocking a specific enzyme in the body. It is not classified as a blood thinner, which prevents clots, or a beta-blocker, which slows the heart rate.


Q: How long does it take for Tritace to start lowering blood pressure?

Clinical pharmacology data suggests that an initial reduction in blood pressure may be observed within one to two hours after the first dose is taken. However, regulatory information states that the maximum, stable blood pressure-lowering effect of any specific dose is generally reached after approximately three to four weeks of consistent treatment.


Q: What happens if I suddenly stop taking Tritace?

Official prescribing information describes that abruptly stopping medicine used to treat high blood pressure may cause an uncontrolled and potentially significant return of high blood pressure. Discontinuing therapy is described as a medical decision that requires professional evaluation.


Q: Why is my doctor checking my blood work when I start taking this medicine?

Regulatory guidance describes the need for monitoring kidney function (such as creatinine and BUN levels) and checking electrolyte levels like potassium before initiating and periodically during therapy. This practice is based on official documents, particularly in patients with pre-existing conditions or those using certain co-administered medications.


Q: Can the side effects of Tritace go away after a few weeks of use?

Certain common side effects, such as feelings of dizziness and low blood pressure (hypotension), are documented in official safety information as being most likely to occur when treatment is first started or when a dose is increased. The potential for the resolution of side effects, including the persistent cough, is also noted generally in prescribing information for this class of medicine.


Q: What does official guidance say about taking alcohol while on Tritace?

Official guidance notes that consuming alcohol can intensify the blood pressure-lowering effect of the medicine. Regulatory documents indicate a potential for increased symptoms, such as dizziness or feeling lightheaded.


Q: Are there known interactions between Tritace and common cold or flu medications?

Regulatory documents specifically include a warning about potential interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common ingredients in many over-the-counter cold and flu preparations. Taking NSAIDs may reduce the blood pressure control provided by Tritace and may increase the risk of reduced kidney function.


Q: Are there any long-term effects of Tritace use discussed in regulatory documents?

Official regulatory documents focus on the medicine's long-term benefits, which include the reduction of major cardiovascular events such as heart attack, stroke, and cardiovascular death, when used over several years. The overall risk profile is defined based on long-term safety data collected during clinical evaluation.


Q: Is it true that Tritace can protect the heart, separate from lowering blood pressure?

Official information describes that Ramipril's action as an ACE inhibitor leads to both a reduction in systemic blood pressure and direct effects on the tissues of the heart and blood vessels. This influence on local systems, which reduces peripheral vascular resistance, is described as contributing to the medicine's overall cardiovascular risk reduction profile.


Q: How is Tritace different from other common blood pressure medicines?

Tritace belongs to the ACE inhibitor class, meaning it works by blocking a specific enzyme (ACE) involved in blood vessel constriction. This differs from other major blood pressure medicine classes, such as Beta-blockers, which primarily work by affecting the heart's rate and force, or Calcium Channel Blockers, which relax blood vessels via a different molecular pathway.


Q: Does Tritace make you feel tired or dizzy when you start taking it?

Official adverse reaction reports state that Dizziness and Fatigue are among the most frequently reported effects from clinical trials. These effects are commonly reported, particularly at the initiation of treatment or following an increase in dose.


Q: Does Tritace affect kidney function?

Official warnings note that when beginning treatment, Ramipril may cause minor and temporary changes in markers used to measure kidney function, especially when taken with a diuretic. Conversely, Ramipril is described in official documents for use in certain kidney conditions, such as diabetic nephropathy, where its effects on protein in the urine have been studied.


Q: What should I avoid eating or drinking while on Tritace?

Regulatory documents advise caution regarding foods or supplements that are high in potassium or any potassium-containing salt substitutes. This is because using Ramipril can increase the risk of elevated potassium levels (hyperkalemia) in the blood.


Q: Is Tritace considered safe for people with diabetes?

Ramipril is approved for use in patients with diabetes for the treatment of high blood pressure and for cardiovascular risk reduction. However, official labeling does include a specific contraindication (a reason not to use the drug) for diabetic patients who are also taking medication containing aliskiren.


Q: Does Tritace cause any weight gain or loss?

Weight changes (both gain and loss) are listed in the official adverse reaction data based on clinical trial experience. While changes in body weight are not listed among the most frequently reported side effects, weight gain is noted in the official regulatory documents.


Q: Can Tritace affect my blood sugar levels?

Official regulatory information, based on post-marketing reports, indicates that there have been rare instances of hypoglycemia (low blood sugar) reported in patients taking Ramipril. This has mainly been observed when the medicine is used in combination with insulin or other oral diabetes medications.


Q: Why might a doctor prescribe a combination pill instead of Tritace alone?

Official dosage guidelines note that Ramipril may be used alone or in combination with other drugs, such as thiazide diuretics. Combination therapy is a documented strategy used to potentially achieve a more effective or targeted blood pressure response when Ramipril alone does not meet therapeutic goals.


Q: Is Tritace linked to any specific skin reactions or rashes?

Official labeling documents report general skin rash as an uncommon adverse event. More severe skin reactions, including those involving blistering and detachment of the skin (e.g., Stevens-Johnson syndrome), are also listed as potentially serious adverse reactions.


Q: Can Tritace affect my sense of taste?

Yes, official product information lists taste disturbance (dysgeusia), which can include changes in or loss of the sense of taste, as an uncommon adverse reaction documented from clinical experience.


Q: How does my eligibility for Tritace change if I have a history of angioedema?

Official regulatory documents define a history of angioedema (serious swelling of the face, throat, or tongue) that was previously linked to any ACE inhibitor treatment as a contraindication. This means the regulatory criteria for use excludes individuals with this specific medical history.


Q: What should be done if I experience a very dry mouth while on Tritace?

Dry mouth (xerostomia) is noted in the official product information as an uncommon adverse reaction. Regulatory documents describe the occurrence of the symptom but do not contain personalized instructions for its management.


Q: Does taking the medicine at night versus the morning make a difference?

The majority of approved uses recommend once-daily dosing, without specifying a time of day for all patients. However, for specific indications like post-myocardial infarction heart failure, official guidance recommends a twice-daily schedule (typically morning and evening) to achieve the full maximum dose.


Q: What are the specific signs of a serious allergic reaction to Tritace?

The most serious allergic reaction described in official documents is angioedema. The signs include swelling of the face, lips, tongue, or throat, which may cause difficulty swallowing or breathing. Other serious, though less common, skin reactions like blistering rashes are also noted.

How should Тритаце be stored and disposed of?

Tritace (ramipril) must be stored and disposed of according to regulatory requirements to ensure product quality and safety.

Storage Conditions

Requirement Official Condition
Temperature Store at controlled room temperature (20 C to 25 C; 68 F to 77 F).
Handling Keep from freezing and away from excess heat.
Protection Store in a closed container away from moisture and direct light.
Child Safety Keep out of the sight and reach of children (lock safety caps).
Stability If capsule contents are mixed for administration, the mixture is stable for 24 hours at room temperature or 48 hours under refrigeration.

Disposal Instructions

Unused or expired Tritace must not be disposed of in household trash or poured down a drain. The product should be discarded following local regulations or by utilizing a drug take-back program (the preferred method). If a take-back program is unavailable, mix the medicine with an undesirable substance (e.g., used coffee grounds), place it in a sealed bag, and throw it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Тритаце found in:

A-Z Index: